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DNA Topoisomerase IBIn the present study, an outline is proposed that may lead to speciﬁc drug design targeting of the Trypanosoma
bruceiDNA Topoisomerase IB. In this direction, an unequivocally speciﬁc platformwas designed for the develop-
ment of selectivemodulators. The designed platform is focused on the unique structural and catalytic features of
the enzyme. Extensive phylogenetic analysis based on all available published genomes indicated a broad distri-
bution of DNA topoisomerases across eukaryotic species and revealed structurally important amino acids which
could be assigned as potentially strong contributors to the regulation of the mechanism of the T. brucei DNA
Topoisomerase IB. Based on the above, we propose a comprehensive in silico 3D model for the structure of the
T. bruceiDNA Topoisomerase IB. Our approach provides an efﬁcient intergraded platformwith both evolutionary
and structural insights for the rational design of pharmacophoremodels as well as novel modulators as the anti-
T. brucei DNA Topoisomerase IB agents with therapeutic potential.
© 2013 Published by Elsevier Inc.1. Introduction
DNA topoisomerases are essential enzymes that control DNA
supercoiling and relieve superhelical tension during transcription, rep-
lication and chromatin assembly by transient DNA strand cleavage and
re-ligation. DNA topoisomerases are broadly divided into two major
families based on the number of DNA strands they cleave, type I
(single-strand) and type II (double-strand), respectively. Type I
enzymes, which introduce a single-stand break, are divided further into
the TopIA and TopIB classes on the basis of their protein architecture
(monomer versus dimer), DNA substrate speciﬁcity (single-strand versus
duplex) and catalytic mechanism. The TopIB enzymes cleave single-
strand DNA and relax both positive and negative supercoiled DNA [1–4].
TopIBmembers have been identiﬁed in eukaryotes, prokaryotes and
viruses [5–10]. TopIB are monomeric enzymes, consisting of an amino-
terminal DNA binding domain, exhibiting variability in both sequence
and length, and possessing a highly conserved carboxy-terminal core
catalytic domain. This domain harbors the invariant tyrosine residue
which attacks the phosphodiester bond of the DNA strand forming a
transient 3′ phosphotyrosyl-enzyme intermediate and nicked DNA
[11–13]. However, in kinetoplastids, which are ﬂagellated protozoaInformatics Team, Biomedical
siou 4, Athens 11527, Greece.
vier Inc.like Trypanosoma brucei and Leishmania donovani, the TopIB enzyme
exists as a dimer, the subunits of which are encoded by two different
genes located at two different chromosomes [14,15]. In the present
study, computational methods were employed to model the three-
dimensional structure of T. brucei TopIB dimeric protein (henceforth
referred to as TbTOP1B) and identify potential drug-like molecules as
targets of this protein. Towards this direction, a comprehensive phylo-
genetic analysis was initially performed; conserved amino acid residues
important for the structure and function of the TOP1B class of enzymes,
as well as residues conserved between the kinetoplastid TOP1B pro-
teins, were identiﬁed. A 3D pharmacophore model based on the struc-
tural and physicochemical properties of the TOP1B binding site was
generated. This pharmacophore model was subsequently used for min-
ing the chemical databases in search for novel small drug-like com-
pounds (Fig. S1).2. Material and methods
2.1. Phylogenetic analyses
2.1.1. Sequence database search
In order to identify homologous TOP1B protein sequences, the non-
redundant publicly available databases: UniProtKB [16], GenBank [17]
and Cyanidioschyzon merolae database [18] were searched with the en-
tire amino acid sequences of all known TOP1Bs applying reciprocal
BLASTp and tBLASTn [19].
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The entire TOP1B amino acid sequences were searched against
PROSITE [20], in order to identify protein domains. The retrieved protein
sequences were aligned using CLUSTALW [21]. To optimize the align-
ment, the amino acid sequences that correspond to the large and small
subunit of the kinetoplastid TOP1B were joined and treated as a single
sequence in the phylogenetic analysis. The resulting multiple sequence
alignment was trimmed by applying Gblocks [22,23] with default op-
tions, and subsequently was used to reconstruct a phylogenetic tree by
employing the neighbor-joining method implemented in MEGA5 [24].
The number of amino acid substitutions per site was estimated using
the JTT model [25]. The robustness of the inferred tree was tested by
performing bootstrap analysis (2000 replicates). The phylogenetic tree
was visualized using Dendroscope [26].
2.1.3. Motif construction
The full-length amino acid sequences of TOP1Bs under study were
aligned and edited by employing Utopia suite's CINEMA alignment edi-
tor [27]. The evolutionarily conserved sequence motifs that were de-
rived from the alignment were submitted to Weblogo [28] in order to
generate consensus sequences.
2.2. Homology modeling
The homologymodeling of the TbTOP1B dimeric proteinwas carried
out using a restraint-based approach, as implemented in the Modeller
package [29]. The crystal structure of the heterodimeric L. donovani
topoisomerase I-vanadate-DNA complex (PDB entry: 2B9S) [30] was
used as template structure. The sequence alignment between the target
sequence of TbTOP1B and the template sequence revealed almost 69%
identity, which allowed for a reliable homology modeling to be per-
formed. The homology modeling process in Modeller starts with the
building of a proﬁle using the “build_proﬁle.py” script. Then the align-
ment was performed using the “align2d” command. As soon as the
alignment between the target and the template was constructed, the
3D model of the target was calculated using the automodel class of
Modeller. Finally, the model was evaluated using the DOPE approach
via the “evaluate_model.py” ﬁle. The overall homology modeling pro-
cess was divided into the following steps: First, the initial spatial con-
straints for the target sequence were derived from a large number of
template protein structures; the target sequence was aligned to the
backbone of a template structure copying the geometric coordinates
of the template to the target sequence. Second, target regions, where
geometric constrains could not be copied from the template easily,
were modeled. These regions represented either deletions or insertions
with respect to the template. The third step involved loop selection and
side chainmodeling, where a collection of independentmodels was ob-
tained. Fourth, the ﬁnal models were scored and ranked, after they had
been stereochemically tested and evaluated with a built-in module for
protein geometry error-checking. Since several models were calculated
for the same target, we had to choose an evaluation method that would
rank them. As mentioned above the DOPE approach was chosen. It is
important to clarify that the DOPE score is not an absolute measure
rather than a relative one. It has only meaning during the relatively
comparison of models that have been generated based on the same ini-
tial alignment. DOPE method is considered more advanced to its rival
GA341 method that is also available by Modeller.
2.2.1. Molecular electrostatic potential (MEP)
Electrostatic potential surfaces were calculated by solving the non-
linear Poisson–Boltzmann equation using ﬁnite difference method as
implemented in the PyMOL Software [31]. The potential was calculated
on grid points per side (65, 65, 65) and the grid ﬁll by solute parameter
was set to 80%. The dielectric constants of the solvent and the solute
were set to 80.0 and 2.0, respectively. An ionic exclusion radius of
2.0 Å, a solvent radius of 1.4 Å and a solvent ionic strength of 0.145 Mwere applied. Amber99 [32] charges and atomic radii were used for
this calculation.2.2.2. Model optimization
The models were initially subjected to energy minimization using
the Gromacs-implemented force-ﬁelds to remove the geometrical strain
[33,34]. Themodel was subsequently solvatedwith Simple Point Charge
(SPC) water using the truncated octahedron box extending to 7 Å from
the model. Molecular dynamics was performed after that at 300 K,
1 atmwith 2 fsecond step size, and for a total of 10 ns, using theNVT en-
semble in a canonical environment; NVT stands for Number of atoms,
Volume and Temperature that remain constant throughout the simula-
tion. The results of the molecular dynamics simulation were collected
into a database by Gromacs which can be subjected to further analysis.2.2.3. Model evaluation
The resultant models were initially evaluated within the Gromacs
package, version 4.5.5 [33,34] by a residue packing quality function,
which depends on the number of buried non-polar side chain groups
and on hydrogen bonding. Moreover, the suite PROCHECK [35] was
employed to further evaluate the quality of the produced TbTOP1B
model. Finally, Verify3D [36] was used to evaluate whether the model
of TbTOP1B is similar to any knownprotein structures. The resultant ho-
mology models were visualized using PyMOL [31].2.3. Design of TbTOP1B speciﬁc ligands
Themodeled 3D structure of the TbTOP1B dimer was used to gener-
ate TbTOP1B speciﬁc ligands by employing LigBuilder2 [37]. To this end,
the structural constrains of the binding pocket of TbTOP1B were ana-
lyzed and ligands were constructed in a stepwise fashion using a library
of fragments. A genetic algorithm, implemented in LigBuilder2, con-
trolled the overall ligand construction process. During construction,
minimization of conformation was performed.
The LigBuilder suite is capable of usingboth the “link” and the “grow”
approaches and to implement a genetic algorithm based search for the
determination of the best structures. The linking procedure, works by
asking the algorithm to select the most suitable moieties to interact
with the active site of the protein and to start linking them together in
a chemically appropriate way. The growing procedure involves the
determination of a group as a starting point and then the growing of a
larger compound that would ﬁt in the active site, while being capable
of establishing interactions with it. It is important that the ﬁrst approach
requires that the user must supply the docking/interaction points of the
moieties that will be used as anchors to the ﬁnal structure. Once the
compounds are drawn from the population, the new population is
formed by combining the information from groups of selected individ-
uals. This is done by randomly splitting the representative strings of
the parents and recombining them to form new entities. This operation
is called Crossover. Because the parents have been selected for their
ﬁtness, the children of these parents will, statistically, be more ﬁt than
the parents. This is done until a new population has been built from
the old one. The ﬁnal step is the evaluation of the new population,
which may result in starting the whole process over again by changing
a single or groups of parameters.
The program took into consideration the ﬂexibility of the ligand,
whereas the protein TbTOP1B was kept rigid. In this way, a database
of novel ligand fragments was generated. The database was further
ﬁltered; thus, the included ligandmolecules exhibited chemical proper-
ties whichwere correlated more strongly to the structural and physico-
chemical characteristics of the receptor binding pocket. A post-ﬁltering
step involved the use of statisticalmethods to deduce a pattern from the
ligand molecules.
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The “Complexed-based” pharmacophoremodule as implemented in
the MOE suite [38] was employed to generate a 3D pharmacophore
model. Initially, a set of Pharmacophoric Annotation Points (PAPs) was
prepared for a series of amino acid residues in the TbTOP1B. These res-
idues were selected based on their degree of conservation among
kinetoplastids (i.e. the residues that were more conserved between
kinetoplastid TOP1Bs and less conserved among other species). This
was achieved by visual inspection of the multiple alignment of the
TOP1B amino acid sequences. The highest ranking 3D pharmacophore
hypothesis, as a grouped 3D arrangement of PAPs, was selected since
it represents the best match to the collective structural and physico-
chemical properties necessary for optimal ligand–receptor interaction.
3. Results/discussion
3.1. Phylogenetic analysis of TOP1B
In the present study, a phylogenetic analysis of TOP1B homologs in
all available genomes, along with domain organization analysis of the
identiﬁed putative proteins, was performed. (See Fig. 1) Based on our
ﬁndings, putative members of the TOP1B family were identiﬁed in the
major eukaryotic and prokaryotic taxonomic divisions, aswell as viruses
(Fig. 2A and Supplementary Table 1). Furthermore, all protein sequences
under study were found to possess ﬁve signature motifs where the ﬁve
catalytically important residues are located, including tyrosine (Fig. 2B).
In eukaryotes, except kinetoplastids, the protein TOP1B exists as a
composite protein (Fig. 2A, blue clade). In archaea, TOP1Bhomologswere
detected as single fused proteins only in the phylum thaumarchaeota
(Fig. 2A, blue clade); after extensive database searches, none of the
two subunits was detected in the archaeal phyla euryarchaeota and
crenarchaeota. The eukaryotic and thaumarchaeal TOP1Bs cluster togeth-
er (Fig. 2A). It is suggested that either thaumarchaeota acquired a TOP1B
gene from eukaryotes through horizontal gene transfer or a TOP1B copy
might have existed also in euryarchaeota and crenarchaeota that got
lost during evolution [39].
In our analysis, in accordance with previous reports [14,15,40], we
found that in kinetoplastids the protein TOP1B is split into its two com-
ponent proteins (Fig. 2A, red clade). There are two alternative possible
hypotheses that could explain this phenomenon. According to the ﬁrst
hypothesis, a single ancestral TOP1B gene probably underwent ﬁssion
and was split into two separate genes. Conversely, two independent
genes may have existed which were fused over time, except in
kinetoplastids. Given that TOP1B proteins are similar in sequence and
mechanism to the tyrosine recombinases [41], Krogh and Shuman sug-
gested that the two enzyme families harbor a common catalytic domain
that fused during evolution with different amino-terminal domains [8].
Over the course of evolution, genes are fused in order to confer advan-
tages such as decrease of the regulational load in the cell for certain pro-
cesses, or to yield new genes with novel functions [42,43]. In a similar
manner, the fusion of the genes encoding the DNA binding and the cat-
alytic domain may have taken place in order to produce the novel gene
TOP1B. However, this is not the case in the kinetoplastid TOP1B, where
there must have been evolutionary pressure to TOP1B to maintain itsFig. 1. Schematic illustration of the drug design process.dimeric architecture, as it allows to the two domains to function inde-
pendently and, also be replaced in case of damage ensuring that the en-
zymatic activity is not interrupted [14].
Furthermore, in the phylogenetic tree in Fig. 2A, the kinetoplastid
TOP1B proteins form a distinct monophyletic branch which is basal to
the clade that corresponds to the other eukaryotic proteins (supported
by a high bootstrap value). This adds further support to the hypothesis
that the kinetoplastid TOP1Bs diverged early from the other eukaryotic
TOP1Bs.
3.2. Homology modeling of the dimeric TbTOP1B
In the present study, the dimeric trypanosome TbTOP1B, was
modeled complexed with a cleaved dsDNA substrate using the se-
quence alignment of Fig. 3. The two protomers together make the
fused protein of the T. brucei DNA Topoisomerase IB. According to this
model, the large DNA binding domain of TbTOP1B clamp wraps around
the substrate DNA and the carboxy-terminal region of the large domain
interacts with the small, catalytic domain (Fig. 4). This is a great oppor-
tunity that distinguishes the T. brucei DNA Topoisomerase from the cor-
responding human one, as through the fusion event it creates a unique
structural conformation for the T. brucei that does not exist in the non-
fused human Topoisomerase. This is very important for the speciﬁcity
of in silico inhibitor screening as well as for reduced expected human
toxicity. The template structure is colored yellow in Fig. 4, while the
ﬁrst component of the fused trypanosome protein is colored green
and the second one is colored blue. The dsDNA substrate is colored
gray. It is clear that due to the relatively high sequence identity (69%),
the model of the trypanosome topoisomerase was very similar in its
3D structural arrangement to its template. The catalytic tyrosine residue
is covalently attached to the nicked DNA backbone. Furthermore, as
suggested by previous studies, although the human and kinetoplastid
TOP1B proteins have different architecture (monomer versus dimer),
the overall structure and catalytic mechanism are highly conserved
[30]. The 3D structure of the trypanosome TOP1B and TbTOP1B was
modeled so that structure-based drug design and pharmacophore eluci-
dation studies could be carried out. The model was then in silico evalu-
ated for its reliability. Firstly, it was structurally superimposed and
subsequently compared to its template, where it exhibited an alpha-
carbon RMSD of less than 0.5 Å (Fig. S1). Furthermore it was evaluated
withMOE andPROCHECK for its geometry (see supplementarymaterial)
and then subjected to the Verify3D algorithm for a more thorough eval-
uation (Fig. S2). Verify3D assessed the compatibility of the 3D model of
Topoisomerase model with its own amino acid sequence. Based on loca-
tion and environment, a structural class is assigned for each residue. A
collection of reference structures is used as a control in order to calculate
a score for each residue. The Topoisomerase model ranged from +0.28
to +0.78. That conﬁrmed that the model is of high quality, since
Verify3D scores below +0.1 are indicative of serious problems in the
model [23].
3.3. Pharmacophore elucidation and virtual screening
Camptothecins are speciﬁc anti-TOP1B agents that act as uncom-
petitive inhibitors that bind to the TOP1B enzymes and substrate
DNA resulting in an immobile ternary complexwhich prevents religation
of the DNA strands [44,45]. The kinetoplastid and mammalian cells ex-
hibit comparable susceptibility to camptothecin [46,47]. This could
be explained by the fact that the residues that are located in the
camptothecin-binding pocket of TOP1B were found to be conserved
between the kinetoplastid Leishmania and human [30].
The aim of our study was the identiﬁcation of selective agents that
speciﬁcally target the kinetoplastid TbTOP1B, avoiding in this way any
harmful side effects on the human host. Towards this end, a set of 12
de novo designed drug-like compounds, which can potentially bind to
TbTOP1B and inhibit its activity, was identiﬁed (Fig. S3). When we
Fig. 2.A) Phylogenetic tree of TOP1B proteins. Bootstrap values (N50%) are shownat the nodes. The length of the tree branches reﬂects evolutionary distance. The scale bar at the upper left
represents the length of amino acid substitutions per position. In some cases, the species commonnameswere used instead. Different colors are used for different taxonomic divisions. The
clades that correspond to specieswhere the TOP1B is fused, are indicated by blue, split by red. B) Sequence logo of the ﬁve catalytic motifs identiﬁed in TOP1B proteins. The height of each
letter represents the frequency of the corresponding aminoacid residue at that position, and the letters are ordered in such away that themost frequent is on the top. The residues essential
for TOPiB catalytic activity are indicated by dots and are numbered according to the human TOP1B.
110 D. Vlachakis et al. / Genomics 103 (2014) 107–113superimposed ourmodeled structure of TbTOP1B with its human coun-
terpart (PDB ID: 1A31) [48], the residues that line the binding site of the
12 ligands were not conserved in the two species; instead they were
speciﬁc to trypanosomes (data not shown).
Subsequently, a 3D pharmacophore model was designed that incor-
porated all spatial and electronic features that are necessary to ensure
optimal non-covalent interactions with the TbTOP1B enzyme (Fig. 5).
Evolutionary information in the form of conserved amino acids was
also taken into account in pharmacophore design in order to increase
the possibility of ﬁnding molecules with drug-like properties that spe-
ciﬁcally target the TbTOP1B protein.
The 3D Pharmacophore design method that was used in this study
was a receptor-structure based one. A pharmacophore elucidation
study was conducted within MOE by automatic detection of possible
cavities as active site. The automatic cavity selection was conducted
using the alpha-sphere cavity detector of MOE. The highest rankingcavity was located next to the interaction site of the two modeled com-
ponents. This is very important, as the structure-based pharmacophore
shared features from both protomers. The ﬁnal pharmacophore model
was the overlaying of 35 different pharmacophores that were reduced
to their common features. In this way, a set of receptor-inhibitor ideal
theoretical interaction ﬁngerprints was deduced. Fig. 5 depicts the 3D
pharmacophore that was established. It was found that the T. brucei
DNA Topoisomerase IB pharmacophore comprised of ﬁve functional
groups: two electron accepting groups (Fig. 5, blue colored), two aro-
matic regions (Fig. 5, green colored) and one electron donating group
(Fig. 5, magenta colored). The ultimate aim for the establishment of
the 3D pharmacophore for the T. brucei DNA Topoisomerase IB was to
enable us to perform ultra fast in silico virtual screening of large drug-
like databases towards the identiﬁcation of putative compounds that
may have anti-T. brucei DNA Topoisomerase IB activity. Collectively, ac-
cording to our in silico prediction model, a potent candidate inhibitor of
Fig. 3. Sequence alignment. Each one of the two fused protomers is aligned against the template Crystal Structure of heterodimeric L. donovani topoisomerase I-vanadate-DNA complex
(RCSB code: 2B9S).
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scribed pharmacophoric features. All pharmacophoric features were
subsequently used as a query to sequentially screen theNational Cancer
Institute (NCI) database of chemical compounds through virtual High
Throughput Screening (vHTS). After a series of in silico docking and
ranking a total of 999 lead compounds were collected that conform to
the pharmacophoric features and can be considered potential TbTOP1B
inhibitors. The highest ranking compound was found to be compound
DV1, which ﬁtted accurately our model in its estimated bioactive con-
formation (Fig. 6). It is obvious that when the DV1 compound is
bound to the T. brucei DNA Topoisomerase IB, it is blocking the DNA
channel, thus inhibiting its passage and its processing by the T. brucei
DNA Topoisomerase IB (Fig. 6A). More speciﬁcally in Fig. 6B, it is clear
that the compound interacting residues Arg481 and Thr228 come
from two different protomers of the T. brucei DNA Topoisomerase IB
model. The two latter residues were found to interact with the DNA
bases in the initial model. Therefore, establishing strong hydrogen
bonding interactions with those amino acids will create a “roadblock”Fig. 4. Homology model of the TbTOP1B heterodimer bound to nicked DNA. A) The DNA bindin
DNA substrate is depicted in gray color. B) Uses same color-conventions as A, but is also a full a
domain is orange atom color.for the incoming DNA oligonucleotide chain. More speciﬁcally the DV1
compound competes with DNA since, its Adenine-like base set of conju-
gated rings, mimics the nucleotide binding form as it occupies the same
3D spatial coordinates of the DNA nucleotide (Fig. 6C). Gly227 stabilizes
the conjugated aromatic rings by establishing hydrophobic, pi-stacking
interactions.
Collectively, herein our aim is to model the three dimensional struc-
ture of the T. brucei DNA Topoisomerase IB towards the development
of a 3D speciﬁc pharmacophore, due to its emerging potential as a phar-
maceutical target suitable for drug design. In an effort to improve our un-
derstanding of residue conservation in the structure of the T. brucei DNA
Topoisomerase IB, a full scale, across species phylogenetic analysis was
conducted. In-depth analysis, cross merging of the phylogenetic and
the structural data resulted in a concise 3D in silicomodel,which explains
and rationalizes the structure of the T. bruceiDNA Topoisomerase IB. The
resulting 3Dmodel suggested a newperspective that led to the establish-
ment of a speciﬁc 3D pharmacophore for the T. brucei DNA Topoisomer-
ase IB.Weused the 3Dmodel and the designed pharmacophore for the ing domain of TbTOP1B is shown in blue, the catalytic domain is indicated by green and the
tom display of the model. The binding domain is magenta atom color, while the catalytic
Fig. 5. The 3D Pharmacophore of the Trypanosoma brucei DNA Topoisomerase IB model structure. Here, the binding domain of TbTOP1B is shown inmagenta and the catalytic domain in
orange color. Purple and blue colors correspond to electron donating and accepting groups, respectively and green to aromatic groups.
Fig. 6. In silico virtual screening. A) The 3D pharmacophore was used to screen the full NCI compound database. B) This compound (DV1) was the highest ranking one as it established
interactions with residues from both protomers of the Trypanosoma brucei DNA Topoisomerase IB model. C) The selected compound clearly blocks the passage of the ssDNA substrate
in the topoisomerase model. The dsDNA is shown in red spaceﬁll format.
112 D. Vlachakis et al. / Genomics 103 (2014) 107–113silico virtual screening of large compound databases that led to the iden-
tiﬁcation of a lead compound as a promising inhibitor, whichwill modu-
late the activity of the enzyme. The present work provides insights for
future drug design of novel compounds with improved biochemical
and clinical characteristics as anti-T. bruceiDNATopoisomerase IB agents.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.ygeno.2013.11.008.
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